A SINGLE ARM, OPEN-LABEL, PHASE 1B TRIAL OF EPCORITAMAB IN PEDIATRIC PATIENTS WITH RELAPSED/ REFRACTORY AGGRESSIVE MATUR B-CELL NEOPLASMS

Registry ID

M20-429

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ABBVIE CORPORATION

Start date

2024-05-01

Completion date

2024-09-10

Last update

2022-02-15

Conditions

• B-CELL MALIGNANCIES

Related clinical trials

• A PHASE I TRIAL OF CLIC-2201 FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL MALIGNANCIES
• A MODULAR PHASE I/II OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD5492, A T CELL-ENGAGING ANTIBODY TARGETING CD20 IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (TITANIUM)
• FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF THE BTK DEGRADER, ABBV-101, IN PARTICIPANTS WITH B-CELL MALIGNANCIES
• A FIRST-IN-HUMAN MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ABBV-319 IN B-CELL MALIGNANCIES
• A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND -EXPANSION STUDY OF THE BRUTON TYROSINE KINASE TARGETED PROTEIN DEGRADER BGB-16673 IN PATIENTS WITH B-CELL MALIGNANCIES
• A MULTICENTER, OPEN-LABEL, PHASE 2 BASKET STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK¿2140 AS A MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH AGGRESSIVE AND INDOLENT B-CELL MALIGNANCIES

View on source registry